365亿蓝海市场开发之路坎坷,复旦张江、正大天晴等多药企遇挫

制药网
Oct 16

根据数据统计,非酒精性脂肪性肝炎(NASH)市场前景广阔,2024年,我国NASH药物市场规模约为16亿元,预计到2030年,这一市场规模将增长至365亿元,2025年-2030年期间,我国NASH药物市场的复合增长率预计为61.4%,这一惊人的增长数据,让 NASH 药物市场成为医药行业备受瞩目的 “蓝海”,吸引了众多药企纷纷布局。然而,与市场广阔前景形成鲜明对比的是,NASH 药物开发之路充满...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10